ROS1 inhibitors are effective in patients with ROS1-positive NSCLC and are used as first-line treatment.30 BRAFV600E mutation, found in 1%–2% of lung adenocarcinomas, acts as an oncogenic driver. Here, ROS1 is linked to lung adenocarcinoma.